Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF): 2013-2024

Historic Depreciation & Amortization (CF) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to $540,000.

  • Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) fell 15.38% to $110,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $463,000, marking a year-over-year decrease of 18.34%. This contributed to the annual value of $540,000 for FY2024, which is 3.45% up from last year.
  • As of FY2024, Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) stood at $540,000, which was up 3.45% from $522,000 recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) registered a high of $540,000 during FY2024, and its lowest value of $120,000 during FY2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $454,000, with a median of $522,000 in 2023.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) crashed by 49.79% in 2021, and later skyrocketed by 150.00% in 2022.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) stood at $239,000 in 2020, then crashed by 49.79% to $120,000 in 2021, then surged by 150.00% to $300,000 in 2022, then skyrocketed by 74.00% to $522,000 in 2023, then climbed by 3.45% to $540,000 in 2024.